DnB Asset Management AS Trims Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• DnB Asset Management AS reduced its stake in Thermo Fisher Scientific by 1.5% during Q1, owning 198,211 shares worth approximately $98.63 million.
• Thermo Fisher Scientific reported a $5.36 EPS for the last quarter, exceeding the consensus estimate, with a revenue of $10.86 billion, reflecting a 2.9% year-over-year increase.
• The company declared a quarterly dividend of $0.43 per share, payable on October 15th, which corresponds to an annual yield of 0.4%.

DnB Asset Management AS lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 198,211 shares of the medical research company's stock after selling 3,070 shares during the quarter. DnB Asset Management AS owned 0.05% of Thermo Fisher Scientific worth $98,630,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Edmond DE Rothschild Holding S.A. grew its position in shares of Thermo Fisher Scientific by 8.9% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 39,503 shares of the medical research company's stock valued at $19,657,000 after acquiring an additional 3,236 shares during the period. EdgePoint Investment Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $172,139,000. Clark Capital Management Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.7% during the 1st quarter. Clark Capital Management Group Inc. now owns 4,475 shares of the medical research company's stock valued at $2,227,000 after acquiring an additional 30 shares during the period. Clifford Group LLC lifted its holdings in Thermo Fisher Scientific by 5.5% during the first quarter. Clifford Group LLC now owns 517 shares of the medical research company's stock valued at $257,000 after purchasing an additional 27 shares in the last quarter. Finally, Belmont Capital LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at $249,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,666 shares of company stock valued at $13,982,763. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 0.6%

Thermo Fisher Scientific stock traded up $2.71 during midday trading on Friday, hitting $492.20. 1,442,575 shares of the stock were exchanged, compared to its average volume of 1,624,930. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock has a market capitalization of $185.86 billion, a price-to-earnings ratio of 28.47, a PEG ratio of 2.63 and a beta of 0.75. The stock's 50-day simple moving average is $460.72 and its 200 day simple moving average is $452.89. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Barclays increased their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, UBS Group raised their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.